EP4582105A3 — Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Assigned to Celgene Corp · Expires 2025-10-08 · 1y expired
What this patent protects
The description provides pharmaceutical compositions in the form of a capsule for oral administration comprising pomalidomide. Also disclosed are pharmaceutical compositions in form of a capsule for oral administration comprising pomalidomide for use in method of treating, preven…
USPTO Abstract
The description provides pharmaceutical compositions in the form of a capsule for oral administration comprising pomalidomide. Also disclosed are pharmaceutical compositions in form of a capsule for oral administration comprising pomalidomide for use in method of treating, preventing or managing cancer of the blood and bone marrow.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.